(R)-3-(2-(2-(4-(4-fluorobenzyl)-2-methylpiperazin-1-yl)-2-oxoethoxy)-5-chlorophenylamino)-4-(2-morpholinoethylamino)cyclobut-3-ene-1,2-dione

ID: ALA234295

Chembl Id: CHEMBL234295

PubChem CID: 44430752

Max Phase: Preclinical

Molecular Formula: C30H35ClFN5O5

Molecular Weight: 600.09

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1Nc1c(NCCN2CCOCC2)c(=O)c1=O

Standard InChI:  InChI=1S/C30H35ClFN5O5/c1-20-17-36(18-21-2-5-23(32)6-3-21)10-11-37(20)26(38)19-42-25-7-4-22(31)16-24(25)34-28-27(29(39)30(28)40)33-8-9-35-12-14-41-15-13-35/h2-7,16,20,33-34H,8-15,17-19H2,1H3/t20-/m1/s1

Standard InChI Key:  PDPPVAWOMSYKMX-HXUWFJFHSA-N

Associated Targets(Human)

CCR1 Tchem C-C chemokine receptor type 1 (1730 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Ccr1 C-C chemokine receptor type 1 (74 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ccr1 C-C chemokine receptor type 1 (38 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 600.09Molecular Weight (Monoisotopic): 599.2311AlogP: 2.67#Rotatable Bonds: 11
Polar Surface Area: 103.45Molecular Species: NEUTRALHBA: 9HBD: 2
#RO5 Violations: 1HBA (Lipinski): 10HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 11.29CX Basic pKa: 6.48CX LogP: 2.49CX LogD: 2.44
Aromatic Rings: 3Heavy Atoms: 42QED Weighted: 0.32Np Likeness Score: -1.72

References

1. Xie YF, Lake K, Ligsay K, Komandla M, Sircar I, Nagarajan G, Li J, Xu K, Parise J, Schneider L, Huang D, Liu J, Dines K, Sakurai N, Barbosa M, Jack R..  (2007)  Structure-activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists.,  17  (12): [PMID:17446072] [10.1016/j.bmcl.2007.03.104]

Source